ADVISORY, Sept. 18, 2009 (GLOBE NEWSWIRE) --
What: Cumberland Pharmaceuticals Inc. (CPIX) will visit the NASDAQ MarketSite in New York City's Times Square to celebrate the company's recent IPO. Cumberland priced its IPO on August 10, 2009, representing the first biopharmaceutical IPO in the U.S. in nearly two years. The company has also recently launched its new Caldolor product, which was approved by the FDA in June 2009 and is an injectable formulation of ibuprofen for treatment of pain and fever. In honor of the occasion, A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals Inc. (CPIX), and Cumberland representatives will ring The NASDAQ Stock Market Closing Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, September 21, 2009 at 4:00 p.m. ET Contacts: Cumberland Pharmaceuticals: Angela Novak (615) 255-0068 anovak@cumberlandpharma.com Lovell Communications: Rebecca Kirkham (615) 297-7766 Rebecca@lovell.com NASDAQ MarketSite: Robert Madden (646) 441-5045 Robert.Madden@NASDAQOMX.com
Feed Information:
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.
Radio Feed:
An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a high-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Cumberland Pharmaceuticals Inc. (CPIX):
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States, and has now completed the commercial launch of that product. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company recently completed the initial public offering of its common stock.
For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with over 3,700 listed companies. NASDAQ OMX Group offers multiple capital raising solutions to companies around the globe, including its U.S. listings market; NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North; and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and ETFs. NASDAQ OMX Group technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX Group exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com.
NDAQA